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The aim of this study was to investigate the effect of 
iontophoresis combined with local psoralen plus ul-
traviolet A (PUVA) therapy in chronic foot eczema. A 
randomized, observer-blinded, multi-centre study was 
conducted in 48 patients with chronic moderate-to-se-
vere foot eczema randomized to one of 3 groups: In the 
iontophoresis group local bath-PUVA was preceded by 
iontophoresis. In the PUVA group only local PUVA was 
given. The corticosteroid group was treated with fluti-
casone. All treatments were given for 8 weeks, with an 
8-week follow-up period. The primary efficacy parame-
ter was eczema score described by Rosén et al. Secondary 
efficacy parameters were a global impression by the pa-
tient, and the Dermatology Life Quality Index (DLQI). 
The eczema score and the DLQI decreased significantly 
over time. There were no significant differences in the 
decrease in eczema score (p = 0.053) and DLQI values 
(p = 0.563) between the 3 treatments. The DLQI values 
in our chronic foot eczema patients were high. There was 
no obvious advantage of local bath-PUVA with or with-
out iontophoresis over local steroid therapy. Key words: 
PUVA therapy; iontophoresis; eczema; foot dermatoses.
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Data on foot eczema (FE) are scarce and are often des-
cribed in connection with hand eczema (1–4). Like hand 
eczema, FE can be classified according to aetiology and 
clinical features. Morphological types of hand eczema are 
vesicular (pompholyx type), hyperkeratotic/rhagadiform/
tylotic, discoid (nummular patches) and combinations of 
these types (5). This classification probably also applies 
to FE.
Chronic eczema of the hands and feet is often re-
fractory to conventional topical treatment such as 
corticosteroids, calcineurin inhibitors and coal-tar deri-
vatives.  Long-term systemic treatments (azathioprine, 
methotrexate, cyclosporine, retinoids and oral cortico-
steroids) are limited by their side-effects.
When a contact allergen is known or suspected, avoid-
ance is the obvious choice, but does not always result in 
remission in FE. This may be explained by the occlusive 
effect of shoes and sweating. Hyperhidrosis is an aggra-
vating factor in patients with palmoplantar pompholyx 
(3). Circumstantial evidence for the role of sweating 
in vesicular forms of hand eczema comes from studies 
demonstrating the efficacy of methods directed against 
hyperhidrosis. Tap-water iontophoresis was reported to 
be effective in an open study (6). In a subsequent study, 
botulinum toxin injections in the hands elicited good 
results in the majority of patients (7).
Another important treatment is photochemotherapy 
with psoralen plus ultraviolet A (PUVA). Local PUVA 
treatment has been used in uncontrolled studies in pal-
moplantar conditions with varying success rates (1, 2, 
4). Better results were observed in vesicular types of 
eczema compared with hyperkeratotic types (1, 2, 4).
Since iontophoresis and local bath-PUVA are mo-
dalities with different mechanisms of action, the com-
bination of these treatments was used successfully in 
4 patients with chronic FE (8). The aim of the current 
study was to investigate further the effect of iontopho-
resis combined with local PUVA therapy on dermatitis 
activity in patients with chronic moderate to severe FE, 
who were responding insufficiently to topical therapy. 
This treatment was compared with local PUVA therapy 




Three treatments were investigated in parallel: (i) iontophoresis 
combined with local bath-PUVA therapy (“ionto+PUVA”); (ii) 
local bath-PUVA therapy only (“PUVA”); and (iii) topical cor-
ticosteroid therapy (“steroid”). The study was performed at 2 
centres: University Medical Center Groningen and St Antonius 
Hospital, Nieuwegein. The study was observer-blinded.
Patients
Patients were eligible when ≥ 17 years old and diagnosed with 
at least 3 months’ duration of moderate-to-severe FE and an 
insufficient response to topical steroids, calcineurin inhibitors 
or coal-tar. Severity was defined according to the hand eczema 
score, as described by Rosén et al. (9). The following characte-
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ristics were evaluated: desquamation, erythema, vesiculation, 
infiltration, fissures and the patient’s view on itch and pain. 
Each variable was assessed on a 4-point scale: none (0), slight 
(1), moderate (2) and severe (3). The maximum combined 
severity score was thus 21. Patients were included when this 
summed score was ≥8.
Enrolment was open to patients with endogenous eczema 
and atopic dermatitis (AD). For AD the definition by the Uk 
Working Party’s diagnostic criteria was used (10). All patients 
were patch-tested. Patients were excluded if they had contact 
allergy, which was considered relevant for the eczema (=pa-
tients indicated an exacerbation of dermatitis after exposure to 
the allergen). Psoriasis and fungal infections were ruled out. 
Patients with concomitant hand eczema were included, but 
dermatitis on other body sites led to exclusion. In addition, all 
patients were tested for type 1 allergy (by prick testing and/or 
specific IgE antibodies).
Further exclusion criteria were: systemic therapy (antihista-
mines excluded) for eczema within 3 months before study entry, 
(local) UV therapy within 3 months before study entry, history 
of abnormal UV sensitivity, phototoxic or cytotoxic drugs, 
history of (pre)malignant skin conditions, metal-containing 
device (cardiac pacemaker, orthopaedic implants, gynaecolo-
gical devices), pregnancy, large erosions which could not be 
protected sufficiently by petrolatum, decreased skin sensitivity 
(polyneuropathy), or history of low compliance with therapy.
At inclusion the following characteristics were evaluated: 
duration of eczema, results of patch testing for contact allergy, 
Fitzpatrick skin type, presence of plantar hyperhidrosis (patient’s 
own view), smoking (if present, the number of pack years) and 
morphological type of eczema (vesicular or hyperkeratotic).
Patients were enrolled from July 2006 until January 2011. 
The study was performed in accordance with the Declaration 
of Helsinki and all applicable amendments. All patients gave 
written informed consent before enrolment and the study was 
approved by the ethics committee at each centre.
Randomization and treatment
Eligible patients were randomized to treatment via computer-
generated random-number tables at each centre.
Tap-water iontophoresis. Tap-water iontophoresis was given 
3 times weekly for 10 min using Hidrex® (GS Hidrex GmbH, 
Wuppertal, Germany). The direct current level was slowly in-
creased, guided by the occurrence of tingling sensations. The 
maximum level was 30 mA. Iontophoresis was immediately 
followed by bath-PUVA.
Bath-PUVA. The psoralen bath was prepared by adding 8 ml 
0.075 g/ml alcoholic stock solution of trimethylpsoralen to 3 l 
tap water to obtain a final trimethylpsoralen concentration of 
0.2 mg/l. The soles were exposed to UVA radiation after soaking 
for 15 min. The initial UVA dose was 0.2 J/cm2 in patients with 
skin type I/II, and 0.3 J/cm2 in those with skin types III–VI. 
Dose increments were 0.2 J/cm2 in patients with skin type I/II, 
and 0.3 J/cm2 in those with skin types III–VI. The dose was not 
increased for one week in case of a slight erythema, followed 
by lower increments (0.1 J/cm2 for skin types I/II, and 0.2 J/cm2 
for skin types III–VI). No treatment was given for one week in 
case of burning, followed by continuation with 70% of the last 
dose, and lower increments.
Irradiation was performed with Waldmann PUVA 180 L 
(Waldmann, Schwenningen, Germany) equipped with Sylvania 
F15W/T8. The irradiance at the surface of the patient’s skin was, on 
average, 16 mW/cm2 (Nieuwegein) and 16.4 mW/cm2 (Groningen).
Steroid treatment. This consisted of fluticasone propionate 
0.05% cream or ointment (GlaxoSmithkline, London, Uk) 
applied initially 2 times daily. This was tapered-off by the 
patients when the dermatitis showed a marked improvement 
on “GIP” (see below).
All patients used emollient ointments ad libitum, and antihis-
tamines when necessary. All treatments were given for 8 weeks, 
followed by an 8-week follow-up period without topical steroid.
Efficacy assessments
The primary efficacy parameter was an eczema score derived 
from the hand eczema severity score as described by Rosén et 
al. (9) at 0, 4, 8, 12 and 16 weeks. Blinded evaluation was per-
formed by a dermatologist (Nieuwegein) or a nurse practitioner 
experienced in eczema scoring (Groningen). Secondary efficacy 
parameters were global impression by the patient (GIP) and the 
patient’s view on plantar hidrosis by means of a 4-point scale 
(“0”, no improvement or worse; “1”, moderate improvement; 
“2”, marked improvement; “3”, cleared). Furthermore, the 
patient’s quality of life was evaluated by means of Dermatology 
Life Quality Index (DLQI), according to Finlay & khan (11), at 
0, 8 and 16 weeks. The DLQI is a composite index with a total 
score that ranges from 0 (best quality of life) to 30 (poorest 
quality of life).
Statistical analysis
Normally distributed data are listed as mean (standard deviation 
(SD)), non-normally distributed continuous data as median (q25, 
q75), nominal/ordinal data via frequencies and cross-tables.
Baseline characteristics were evaluated via analysis of va-
riance, including treatment and centre as factors for normally 
distributed data or via kruskal–Wallis test for non-normally 
distributed data.
This study describes time-dependent observations, which are 
correlated by definition. The appropriate analytical approach in 
such cases is the random intercept, random coefficient linear 
mixed model (12). Parameters, such as the eczema score and 
DLQI, are regressed on time (= weeks of treatment) and time 
is considered to be the random factor. Other relevant factors, 
such as “treatment group”, “centre” were introduced into the 
analysis as independent fixed factors, and their interaction with 
time. The latter informs on whether the differences between 
treatments and centres are constant over time.
Global impression by the patient and the patient’s view on 
plantar hidrosis are ordinal 4-point scale parameters. For these 
variables the generalized estimation equations analyse for time-
dependent ordinal parameters were used.
SPSS 19 was used and p-values < 0.05 were considered 
significant. Evaluation is according to the intention-to-treat 
principle.
RESULTS
A total of 48 patients entered the study. Nineteen pa-
tients were allocated to iontophoresis with local PUVA 
therapy (“ionto+PUVA”), 14 to local PUVA therapy 
alone (“PUVA”), and 15 to topical fluticasone (“ste-
roid”). Of these, 5 patients in the ionto+PUVA group, 6 
patients in the PUVA group and 2 patients in the steroid 
group did not complete the trial (Fig. 1). Taken together, 
27% of the patients discontinued after allocation.
The 3 treatment groups did not differ in any of the 
baseline characteristics (Table I). The discontinued 
patients groups did not differ in any of the baseline 
characteristics (data not shown).
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Two patients in the ionto+PUVA group and 3 patients 
in the PUVA group experienced burning during therapy. 
Burning in combination with the lack of efficacy was, 
for these patients, the main reason to withdraw from 
the study. One patient in each group had mild ery-
thema. These side-effects disappeared after adjusting 
the UVA dose.
The mean cumulative values for UVA dose (± SD) 
in the ionto+PUVA group and PUVA group were 27.3 
and 31.2 J/cm2, respectively. The mean cumulative 
value for iontophoresis dose in the into+PUVA group 
was 245 mA.
The time-dependent decrease in eczema score, bro-
ken down by treatment group, is shown in Fig. 2. The 
decrease in the eczema score over time (irrespective of 
the type of treatment) was highly significant (p < 0.001), 
from an initial 10.69 to 6.87 points at end-observation. 
The differences between the 3 treatments on the ec-
zema score was not significant (p = 0.053), and the 
treatment*time interaction (p = 0.075) was also not 
significant. The latter indicates that the decrease in the 
eczema score over time was not different between the 3 
treatment groups. The centre*time interaction was not 
significant (p = 0.778): the eczema score decreased by 
similar levels over time at both centres.
Neither the type of eczema (vesicular vs. hyperkera-
totic) (p = 0.498) nor the presence of hidrosis (p = 0.127) 
predicted the decrease of the eczema score over time. 
The same was true for the variables age, sex, duration 
of eczema and smoking (data not given).
The time-dependent decrease in DLQI score broken 
down by the treatment group is shown in Fig. 3. The 
decrease in the DLQI score over time was highly sig-
nificant (p < 0.001), from an initial 12.23 to 7.78 points 
at end-observation. However, neither the difference 
between the 3 treatments on the DLQI score was signi-
ficant (p = 0.563), nor was the treatment*time interaction 
(p = 0.564). The type of eczema (vesicular vs. hyperke-
ratotic) (p = 0.042) was a weak significant predictor of 
the overall DLQI score. Hyperkeratotic eczema elicited 
a 3.15 higher DLQI score (95% CI 0.12–6.187). The ec-
zema type*time and the eczema type*centre interactions 
were both non-significant (p = 0.554 and p = 0.937, re-
spectively). Therefore, the eczema type had no influence 
on the effect of treatments. The presence of hyperhidrosis 
Fig. 1. Participant flow through the trial. PUVA: psoralen plus ultraviolet A.
Table I. Characteristics of the patients at baseline
ionto+PUVA 
(n   = 19)
PUVA 
(n   = 14)
Steroid 
(n   = 15)
Age, years, mean (SD) 37.9 (11.5) 38.6 (11.1) 41.6 (11.6)
Males/females, n 8/11 10/4 6/9
Endogenous/atopic, n 12/6 11/3 13/2
Duration of eczema, years,  
  mean (SD)
4.6 (4.6) 4.9 (4.4) 6.4 (10.1)
Rosén score, mean (SD) 10.1 (2.1) 10.8 (2.4) 11.8 (3.4)
Dermatology Life Quality Index, 
  mean (SD)
13.4 (5.7) 11.2 (4.3) 11.8 (6.0)
Plantar hyperhidrosis yes/no, n 8/11 10/4 8/7
Smoking yes/no, n 11/8 11/3 11/4
Morphological type, n
  Vesicular 14 4 11
  Hyperkeratotic 5 10 4
Centre, n
  Groningen 9 11 9
  Nieuwegein 10 3 6
SD: standard deviation; ionto: iontophoresis; PUVA: psoralen plus ultraviolet A.
Fig. 2. Eczema score over time. PUVA: psoralen plus ultraviolet A; ionto: 
iontophoresis.
Fig. 3. Dermatology Life Quality Index (DLQI) over time. PUVA: psoralen 
plus ultraviolet A; ionto: iontophoresis.
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was a non-significant (p = 0.078) predictor of the DLQI 
score decrease over time. When DLQI over time is the 
dependent variable no influence was noted of treatment, 
time, centre, type of eczema and hyperhidrosis.
The decrease in the GIP score over time was non-
significant (p = 0.828), from an initial median 1 to 0 
points at end-observation. 
The degree of hidrosis as judged by the patients 
decreased over time only in the ionto+PUVA group 
(p = 0.143 for differences between groups).
DISCUSSION
This study investigated the efficacy of iontophoresis 
combined with local bath-PUVA, and the efficacy was 
compared with that of topical steroids and local bath-
PUVA only. There were no significant differences be-
tween these 3 treatments for the decrease in the eczema 
score and DLQI values. DLQI values in these chronic 
FE patients were high, particularly for hyperkeratotic 
eczema. Eczema type or hyperhidrosis had no influence 
on the effects of treatments with respect to the eczema 
score and DLQI. 
An eczema severity score was chosen as the primary 
efficacy parameter for dermatitis severity (9). This 
composite instrument measures several objective and 2 
subjective characteristics of hand eczema. It is not vali-
dated for FE, but no validated instruments to assess FE 
severity are available. DLQI is a well-known measure 
for estimating quality of life, validated for various der-
matological conditions (11) but not specifically for FE. 
Local bath-PUVA is a widely accepted and effective 
second-line modality in the treatment of hand and foot 
eczema (13). Therefore, we decided not to include a pla-
cebo arm in this study on ethical grounds. The high di-
sease burden and the well-known effects of the reference 
therapies eliminate the need for a placebo-controlled 
study. 
The high drop-out rate of 27% may be considered a 
potential source of bias, as most of the drop-outs were 
due to non-efficacy or side-effects not outweighing 
efficacy. Such subjects may negatively influence the 
overall efficacy estimates of the 3 therapies. Excluding 
these subjects from the analysis would falsely aug ment 
therapeutic efficacy estimates. Fortunately, the statisti-
cal method used to evaluate the data is not sensitive to 
premature drop-out. Per subject the decline over time 
of the parameters is estimated and a minimum of 2 
data-points is needed for that. So a late drop-out (after 2 
data-points), due to, for example, non-efficacy, provides 
an estimate of decline and, when this is low or negative, 
the overall group efficacy is influenced by this. Once 
again, the discontinued patients did not differ in any of 
the baseline characteristics.
The decrease in the eczema score in our study was 
approximately 4 points (over the 3 treatments) and we 
consider this decrease as clinically highly relevant. In 
previous studies on FE, local PUVA induced complete 
remission or marked improvement in 80–89% of the 
patients (1, 2). However, these studies had an open de-
sign and were not blinded (1, 2). Furthermore, dermatitis 
severity at baseline was also not stated, and the thera-
peutic response was graded only qualitatively. In a more 
recent investigation local PUVA was compared with 
oral PUVA in a randomized observer-blinded manner 
(4). The treatment effects were scored with a modified 
Psoriasis Area and Severity Index (PASI) system, and 
that score decreased from 11.5 to 3.7 for local PUVA, 
with a similar decrease for oral PUVA (p = 0.67 for the 
difference between treatments) (4). In a study on vesi-
cular hand eczema topical PUVA was compared with 
UVA without psoralen in a right–left patient-blinded 
way (14). Both PUVA and UVA treatments resulted in a 
significant decrease from 27 to 9 on a semi-quantitative 
scoring scale after 8 weeks therapy, without a difference 
between the 2 treatments (no p-values reported). 
In previous studies better results were observed for 
vesicular, as opposed to hyperkeratotic, eczema types 
(1, 2, 4). In hyperkeratotic eczema bath-PUVA resulted 
in a moderate improvement, whereas oral PUVA had a 
significantly better response, presumably because of 
impaired penetration of 8-methoxypsoralen through the 
thickened epidermis (4). 
In a small open observational study on the combina-
tion of iontophoresis with local PUVA (8) clearance 
or marked improvement was observed in 4 out of 5 
treatments, but the current better designed investigation 
could not confirm the alleged superiority of the combi-
nation therapy. In another (right–left) study on vesicular 
hand eczema, iontophoresis had a favourable effect on 
vesicles and pruritus scores, but not on erythema and 
scaling scores (6). In that study the same iontophoresis 
device was used as in our study, and was given daily 
for 3 weeks. No mention was made of the cumulative 
mA values or of the presence of hyperhidrosis (6). It is 
difficult to compare the outcome of that study with that 
of our study because of lack of details.
Comparison of the results of the above-mentioned 
studies is hampered by the fact that different scoring sys-
tems were used in small unbalanced groups, evaluated 
by statistical methods that did not meet the appropriate 
standards. In contrast, our results are based on the best 
available scoring systems and are analysed by appro-
priate statistics, which were interpreted strictly. These 
powerful analyses point towards the notion that there is 
no additional advantage of local PUVA with or without 
iontophoresis over local steroid therapy.
The DLQI score showed a significant decrease over 
time, with no differences between the treatment groups. 
There was no influence of eczema type on this decrease, 
although the hyperkeratotic type was generally as-
sociated with lower quality of life than the vesicular 
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type. The overall DLQI score at baseline was 12.2. 
To our knowledge, there are no data on quality of life 
for FE, in contrast to those for hand eczema. For hand 
eczema reported DLQI scores were 9.7 (15) and 8.0 
(16). In their original description Finlay & khan (11) 
measured the DLQI in a variety of skin diseases and 
healthy controls. The highest value was 12.5, found in 
AD patients. The high DLQI values in our study may 
be due to a more severe dermatitis. Thus, apparently 
in our groups FE is characterized with a high disease 
burden, comparable with that in AD, but higher than 
that in hand eczema. This high DLQI found in our FE 
patients is remarkable in view of the fact that the feet are 
supposedly not involved in the DLQI items leisure and 
personal relationships to the same extent as in AD and 
hand eczema. Our study showed higher DLQI values in 
hyperkeratotic eczema vs. vesicular eczema. For hand 
eczema no DLQI differences between vesicular and 
hyperkeratotic forms were observed (16). It is unclear 
whether this discrepancy is due to the unique character 
of FE as opposed to hand eczema. DLQI may influence 
patient-rated severity score and may be responsible for 
the discrepancy between the patient-rated and physici-
an-rated scores in hand eczema (15). Our findings on 
FE must await further confirmation in future studies.
A significant benefit of combined iontophoresis–bath-
PUVA in comparison with bath-PUVA only and topical 
steroid therapy could not be demonstrated in this study. 
All treatments induced improvement. These results 
may be because of the study design using a comparison 
be tween 3 active treatments. Introducing a placebo 
group is unethical given the high disease burden in our 
patients. Moreover, it makes more sense to compare the 
efficacy of the novel therapy with a first-line treatment 
(in this case topical steroids) (17). To the best of our 
knowledge, there are only 2 comparative studies on 
palmoplantar eczema without a placebo group (4, 14). In 
those studies too, no differences were observed between 
the treatment groups, which consisted of UVA therapy 
only. Our study has demonstrated that in each treatment 
group there were responders and non-responders. This 
is probably caused by the fact that patients behave dif-
ferently by genetic mechanisms and also by the fact that 
they may become resistent to previously given therapies. 
In dermatological practice topical steroid treatment is 
regarded as a first choice. Therefore, local bath-PUVA 
may be offered when patients are resistent to local 
steroids.
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